Existing research indicates that ACLY is expressed highly in a wide range of cancers, including colorectal, liver, gastric, and prostate cancers, making ACLY a potentially effective therapeutic target for cancer by affecting lipid metabolism [102–106]. Here, ACLY is linked to prostate cancer.